^Somohano MD, Broissin MC, Sobrino ZA (1976). "[Clinical evaluation of oxypertine in anxiety conditions]". Neurologia, Neurocirugia, Psiquiatria (in Spanish). 17 (3): 171–180. PMID12484.
^Breulet M, Labar P, Delree C, Collard J, Bobon J (February 1968). "[Oxypertine, peperazine derivative of tryptophan with neuroleptic and dynamogenic properties]". Acta Neurologica et Psychiatrica Belgica (in French). 68 (2): 116–127. PMID4972600.
^Bak IJ, Hassler R, Kim JS (1969). "Differential monoamine depletion by oxypertine in nerve terminals. Granulated synaptic vesicles in relation to depletion of norepinephrine, dopamine and serotonin". Zeitschrift für Zellforschung und Mikroskopische Anatomie. 101 (3): 448–462. doi:10.1007/BF00335580. PMID5362847. S2CID32583722.